Non‐melanoma skin cancer as a clinical marker for internal malignancies: a nationwide population‐based cohort study

2020 ◽  
Vol 34 (4) ◽  
pp. 746-753 ◽  
Author(s):  
S.J. Yun ◽  
J.M. Bae ◽  
H. Kim ◽  
B.C. Park ◽  
J.S. Kim ◽  
...  
Keyword(s):  
Cohort Study ◽  
Skin Cancer ◽  
Population Based ◽  
Clinical Marker ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals Non-melanoma Skin Cancer and Ten-year All-cause Mortality: A Population-based Cohort Study

2010 ◽  
Vol 90 (4) ◽  
pp. 362-367 ◽  
Author(s):  
A Jensen ◽  
AL Lamberg ◽  
JB Jacobsen ◽  
A Braae Olesen ◽  
HT Sørensen
Keyword(s):  
Cohort Study ◽  
Skin Cancer ◽  
Population Based ◽  
Non Melanoma Skin Cancer ◽  
All Cause Mortality ◽  
Melanoma Skin

scholarly journals Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study

Rheumatology ◽  
2018 ◽  
Vol 58 (4) ◽  
pp. 683-691 ◽  
Author(s):  
François Montastruc ◽  
Christel Renoux ◽  
Sophie Dell’Aniello ◽  
Teresa A Simon ◽  
Laurent Azoulay ◽  
...  
Keyword(s):  
Cohort Study ◽  
Skin Cancer ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Non Melanoma Skin Cancer ◽  
Increased Risk ◽  
Significant Difference ◽  
Specific Cancer ◽  
Risk Of Cancer ◽  
Melanoma Skin

Abstract Objective To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated with an increased risk of cancer overall and by specific cancer sites (breast, lung, lymphoma, melanoma and non-melanoma skin cancer). Methods We performed a population-based cohort study among patients newly treated with bDMARDs within the US-based Truven MarketScan population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate hazard ratios and 95% CIs of any cancer (and specific cancers) associated with initiation of abatacept, compared with initiation of other bDMARDs, adjusted for age and deciles of the propensity score. Results The cohort included 4328 patients on abatacept and 59 860 on other bDMARDs, of whom 409 and 4197 were diagnosed with any cancer during follow-up (incidence rates 4.76 per 100 per year and 3.41 per 100 per year, respectively). Compared with other bDMARDs, the use of abatacept was associated with an increased incidence of cancer overall (hazard ratioadjusted 1.17; 95% CI 1.06, 1.30). Analyses by specific cancer sites showed a significantly increased incidence of non-melanoma skin cancer (hazard ratioadjusted 1.20; 95% CI 1.03, 1.39), but no significant difference for other specific cancer sites. Conclusion The use of abatacept as first bDMARD in the treatment of RA was associated with a slight increased risk of cancer overall and particularly non-melanoma skin cancer, compared with other bDMARDs. This potential signal needs to be replicated in other settings.

Socioeconomic status and non-melanoma skin cancer: A nationwide cohort study of incidence and survival in Denmark

2010 ◽  
Vol 34 (6) ◽  
pp. 689-695 ◽  
Author(s):  
M. Steding-Jessen ◽  
F. Birch-Johansen ◽  
A. Jensen ◽  
J. Schüz ◽  
S.K. Kjær ◽  
...  
Keyword(s):  
Socioeconomic Status ◽  
Cohort Study ◽  
Skin Cancer ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin
Sign in / Sign up

Export Citation Format

Share Document